We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+28.17%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.72B
AUM Growth
+$1.22B
Cap. Flow
+$567M
Cap. Flow %
9.91%
Top 10 Hldgs %
84.78%
Holding
119
New
24
Increased
23
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.2M
2
MDCO
Medicines Co
MDCO
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.9M
4
INCY icon
Incyte
INCY
+$9.54M
5
NKTR icon
Nektar Therapeutics
NKTR
+$7.71M

Top Sells

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$27M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M
4
ZTO icon
ZTO Express
ZTO
+$6.21M
5
SAGE
Sage Therapeutics
SAGE
+$6.14M

Sector Composition

Rank Sector Weight
1 Consumer Staples 34.97%
2 Healthcare 25.04%
3 Consumer Discretionary 17.19%
4 Financials 0.66%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
101
DELISTED
Adaptimmune Therapeutics
ADAP
$1.35M 0.02%
300,000
– –
KDNY
102
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.14M 0.02%
20,000
– –
VSTM icon
103
Verastem
VSTM
$539M
$1.09M 0.02%
+41,667
New +$1.06M
IMDX
104
Insight Molecular Diagnostics
IMDX
$147M
$780K 0.01%
7,500
– –
NDRM
105
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$748K 0.01%
25,000
– –
NVAX icon
106
Novavax
NVAX
$1.22B
$575K 0.01%
25,000
– –
XENE icon
107
Xenon Pharmaceuticals
XENE
$6.18B
$473K 0.01%
150,000
– –
DMTX
108
DELISTED
Dimension Therapeutics, Inc
DMTX
$340K 0.01%
234,493
– –
AAL icon
109
CALL
American Airlines Group
AAL
$9.99B
– –
-500,000
Closed -$21.1M
BABA icon
110
CALL
Alibaba
BABA
$280B
– –
-150,000
Closed -$16.2M
BABA icon
111
Alibaba
BABA
$280B
– –
-250,000
Closed -$27M
INTC icon
112
Intel
INTC
$435B
– –
-100,000
Closed -$3.61M
JPM icon
113
CALL
JPMorgan Chase
JPM
$925B
– –
-200,000
Closed -$17.6M
META icon
114
CALL
Meta Platforms (Facebook)
META
$1.51T
– –
-125,000
Closed -$17.8M
OIH icon
115
CALL
VanEck Oil Services ETF
OIH
$1.99B
– –
-25,000
Closed -$15.4M
REGN icon
116
CALL
Regeneron Pharmaceuticals
REGN
$72.7B
– –
-75,000
Closed -$29.1M
VRTX icon
117
CALL
Vertex Pharmaceuticals
VRTX
$123B
– –
-100,000
Closed -$10.9M
LOXO
118
DELISTED
Loxo Oncology, Inc
LOXO
– –
-65,000
Closed -$2.73M
CELG
119
CALL
DELISTED
Celgene Corp
CELG
– –
-250,000
Closed -$31.1M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2017 Portfolio in Review

As of Q2 2017, Artal Group held 119 positions worth $5.72B, up 27% from $4.51B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group deployed $567M of net new capital in Q2 2017, opening 24 new positions and adding to 23 existing holdings. Its largest new stake was Goldman Sachs: 100,000 shares worth $22.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 35% of assets, down from 45% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Athene Holding Ltd. Class A Common Shares, an estimated $12.8M trimmed.

  • Artal Group's largest Q2 2017 buy was Goldman Sachs: 100,000 shares worth $22.2M.
  • Artal Group added most to Medicines Co in Q2 2017, an estimated $11.1M increase.
  • Artal Group's biggest Q2 2017 reduction was Athene Holding Ltd. Class A Common Shares, cutting an estimated $12.8M.
  • Artal Group fully exited Alibaba in Q2 2017, selling an estimated $27M.
  • Artal Group's ten largest holdings make up 85% of its $5.72B portfolio in Q2 2017.
  • Artal Group opened 24 new positions and closed 11 in Q2 2017.
  • Artal Group's portfolio value rose 27% quarter-over-quarter to $5.72B.

Based on Artal Group's 13F filing for Q2 2017, filed 11 Aug 2017.